Budget Impact Analysis (BIA)
Also known as: BIA, financial impact assessment, budget consequence analysis
Budget impact analysis estimates the financial consequences (net costs or savings) of implementing a new health technology in a specific healthcare system or population over a short time horizon (typically 1–5 years). Distinct from cost-effectiveness analysis (which compares health outcomes per dollar), BIA answers a budgetary question: 'If we adopt this new drug/device, how much will it cost our health system next year?' Widely used by hospital procurement committees, insurance formularies, and government health budgets to assess financial feasibility and reimbursement decision.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
When a new health technology is being considered for adoption and decision-makers need to know the budgetary impact. Standard requirement from payers: CADTH (Canada), NICE (UK), regional insurance funds demand BIA alongside CEA for reimbursement decisions. Use for: pharmaceutical pricing negotiations; device procurement decisions; formulary changes; service expansion planning; healthcare budget forecasting. Mandatory in most developed countries when submitting for reimbursement approval. Not needed for: academic research (non-applied); interventions with negligible cost differences; when budget is not a constraint.
Strengths & limitations
- Directly informs reimbursement/budgeting decisions: payers can see true financial impact and plan ahead, avoiding surprise budget overruns.
- Complements CEA: even if drug is cost-effective, BIA reveals affordability constraints. Combined CEA + BIA gives complete picture.
- Transparent, traceable: all cost and utilization assumptions are explicit, enabling scrutiny by finance teams and clinicians.
- Supports negotiation: pharmaceutical companies can propose price reductions or managed entry agreements (e.g., 'We'll lower price to $1,500/patient, reducing budget impact by 25%') based on BIA results.
- Short time horizon (1–5 years): does not capture long-term benefit (cost offsets from prevention, mortality reduction) that might justify initial budget increase. CEA (10+ year horizon) shows this better.
- Static population: assumes population size and prevalence fixed; BIA does not account for aging population or disease prevalence trends.
- Uptake forecasting is uncertain: market penetration depends on clinical factors (safety profile, efficacy in real world), adherence, and physician behavior. Forecast error propagates to budget impact.
- Does not address equity: a low-cost generic and a high-cost branded drug may have similar BIA if uptake is low, but equity/access implications differ. BIA does not flag this.
- Simplistic cost model: assumes direct medical costs only; does not capture spillovers (reduced lost work days, caregiver burden, quality of life) that CEA includes.
Frequently asked
How is 'market uptake' or 'market penetration' forecast for BIA?
Methods vary: (1) expert opinion (clinicians estimate what % of eligible patients will use new drug); (2) comparative analysis (lookup similar drug's adoption trajectory over 5 years in same market); (3) diffusion model (logistic curve fitting prior adoption patterns in market); (4) discrete choice model (survey clinicians/patients on willingness to switch). Uncertainty is high; BIA should test low, base, and high uptake scenarios in sensitivity analysis.
Should BIA include cost offsets from prevented complications (e.g., avoided strokes, hospitalizations)?
Yes, if data are available. If new drug reduces cardiac events by 20%, calculate hospitalization costs averted and include in BIA. However, quantifying offsets is challenging and requires modeling disease progression. Many BIAs conservatively exclude offsets (showing worst-case budget impact); if offsets are included, clearly document assumptions and cite source data.
What discount rate should be used in BIA?
Standard: 0–3% annually. BIA time horizons are short (1–5 years), so discounting is minimal. Most use 0% (undiscounted) for simplicity; 3% is standard if longer horizon (>5 years). Rationale: healthcare budgets are year-to-year; short-term impact matters. Contrast with CEA, which discounts 3–5% over 10+ years (long-term efficiency focus).
Can BIA be used to compare two new drugs with similar efficacy but different costs?
Yes. BIA will show which has lower budget impact. However, if two drugs are clinically equivalent, clinical choice is often cost-driven; BIA provides that cost signal. Complement with CEA to ensure both are cost-effective vs current standard; then BIA guides choice between two acceptable options.
How do managed entry agreements (MEAs) relate to BIA?
MEAs are pricing/reimbursement contracts that reduce budget impact. Examples: (1) Conditional coverage ('fund only for patients meeting criteria'), which limits uptake. (2) Price discounts ('Reduce price to $X per patient to achieve target budget impact'). (3) Outcomes-based rebates ('If drug fails to meet efficacy targets, manufacturer refunds difference'). Manufacturer and payer negotiate using BIA results: 'Current price + projected uptake = $5M budget impact; to achieve $2M, we need price cut to $X or restrict to subgroup Y.'
What is the difference between BIA and 'financial impact analysis'?
BIA is a specific methodology (Sullivan et al. guidelines) for healthcare. Financial impact analysis is broader, applied to any project (IT system, facility renovation) to forecast budget consequences. In healthcare context, BIA and financial impact analysis are synonymous; BIA is the standard term.
Sources
- Sullivan, S. D., Mauskopf, J. A., Augustovski, F., et al. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14. DOI: 10.1016/j.jval.2013.08.2291 ↗
- Klok, R. M., Brouwers, J. R., Postma, M. J., et al. (2005). Budget-impact analysis: a systematic literature review of implementation studies. The Annals of Pharmacotherapy, 39(3), 518-526. link ↗
- Canadian Agency for Drugs and Technologies in Health (CADTH). (2017). Guidelines for the Economic Evaluation of Health Technologies: Canada (4th ed.). Ottawa: CADTH. link ↗
How to cite this page
ScholarGate. (2026, June 4). Budget Impact Analysis (BIA). ScholarGate. https://scholargate.app/en/health-economics/budget-impact-analysis
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cost-Benefit AnalysisHealth Economics↔ compare
- Cost-Effectiveness AnalysisHealth Economics↔ compare
- Decision Analytic ModelingHealth Economics↔ compare
- Markov Model in Health EconomicsHealth Economics↔ compare
- Quality-Adjusted Life YearHealth Economics↔ compare